TNF and tuberculosis: Conversely, multiple studies have shown that patients with autoimmune disorders who are treated with the current generation of general TNF inhibitors (e.g., etanercept, infliximab, adalimumab) are at increased risk of tuberculosis and certain malignancies including melanoma [47–49].